In one aspect, the disclosure relates to new cannabidiol (CBD) analogs produced from allylic monoterpene alcohols and substituted resorcinols in the presence of aryl boronic acids, efficient and mild synthetic methods of making the new CBD analogs, and improved methods of making known CBD analogs. In one aspect, the methods produce low amounts of tetrahydrocannabinol (THC)-like compounds, low amounts of abnormal cannabidiol (abn-CBD) analogs, and higher amounts of CBD analogs, greatly simplifying purification. The methods can be tailored further to produce low amounts of CBD analogs and higher amounts abn-CBD analogs. In the disclosed methods, synthesis parameters can be varied in order to selectively produce a desired normal or abnormal regioisomer.
C07C 39/19 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with unsaturation outside the aromatic ring containing carbon-to-carbon double bonds but no carbon-to-carbon triple bonds
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
2.
COMPOUNDS FOR THE TREATMENT OF RETINITIS PIGMENTOSA AND METHODS OF MAKING AND USING THE SAME
In one aspect, the disclosure relates to substituted N-acetylated cysteine- and selenocysteine-based compounds. Also disclosed are methods of making the same, pharmaceutical compositions comprising the same, and methods of treating eye disorders including retinitis pigmentosa (RP) using the same. In some aspects, the compounds can also have antimicrobial activity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
3.
PHOTOCHEMICAL FOOTPRINTING OF TARGETED PROTEINS FROM MAMMALIAN BODILY FLUIDS
In one aspect, the disclosure relates to methods and systems for evaluating the higher-order structure of a target biomolecule, such as, for example, a protein, within a biological fluid. The biological fluid can be isolated from a mammal or another multicellular host and subjected to the method without further processing steps. In an aspect, the biological fluid is labeled to produce a labeled target biomolecule, which can then be analyzed using LC-MS/MS or another technique to produce a labeled target molecule profile, which can be compared to an LC-MS/MS profile of the unlabeled target biomolecule, wherein m/z and retention times of the labeled target biomolecule or degradation products thereof can be compared to those for unlabeled target biomolecules in order to elucidate details about the structure of the target biomolecule including locations of solvent-accessible residues, conformation changes in a particular extracellular environment, drug-target biomolecule interactions, and the like.
4.
CANNABICHROMENE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME
Described herein are new derivatives of cannabichromene that are effective in treating or preventing pain in a subject. The new cannabichromene derivatives have improved bioavailability, which enhances their ability to treat or prevent pain. In one aspect, the cannabichromene derivatives have the structure I or the pharmaceutically acceptable salt thereof. Also described herein are methods for making and using the cannabichromene derivatives.
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
5.
FLUOROALCOHOLS AS CO-SOLVENTS FOR CHEMICAL SYNTHESIS AND METHODS FOR PRODUCING THE SAME
gemgem-diols and can be conducted under mild conditions with high yields. Also disclosed herein are pentafluoroisopropanols generated by the disclosed method and methods of using the pentafluoroisopropanols as solvents and co-solvents for organic synthesis, metal catalyzed reactions, asymmetric processes, carbohydrate chemistry, and medicinal chemistry.
C07C 41/09 - Preparation of ethers by dehydration of compounds containing hydroxy groups
C07C 45/63 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by introduction of halogenPreparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reactions not involving the formation of C=O groups by substitution of halogen atoms by other halogen atoms
C07C 45/82 - SeparationPurificationStabilisationUse of additives by change in the physical state, e.g. crystallisation by distillation
C07C 45/78 - SeparationPurificationStabilisationUse of additives
6.
METHODS FOR THE PULSED DELIVERY OF BIOACTIVE AGENTS
Described herein are methods for providing the pulsed delivery of a 5HT2A agonist to a subject upon administration of a device to the subject. The device is composed of biodegradable polymers such that when administered to the subject, the polymers on the surface of the device erode, releasing the bioactive agent. In one aspect, the device is composed of alternating layers of biodegradable polymers, where every other layer includes the bioactive agent. In a further aspect, one or more of the layers are composed of a mixture of cellulose acetate phthalate (CAP) and a poloxamer. The layers that do not include the bioactive agent functions as “blanks,” which can be used to control the release rate of the bioactive agent. In a still further aspect, one or more sides of the device can be coated such that the bioactive agent is released from only one side of the device.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/48 - Ergoline derivatives, e.g. lysergic acid, ergotamine
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Described herein are methods for reducing or preventing intraocular pressure in a subject. The methods involve administering to the subject a delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor. The combination of delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor is effective in reducing intraocular pressure when compared to independently the delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor.
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Disclosed herein is a device for delivering one or more bioactive agents, the device comprising a first layer comprising a first biodegradable polymer, wherein the first layer has a first and a second side, and wherein a plurality of reservoirs comprising one or more bioactive agents are present on the first side; a second layer comprising a second biodegradable polymer, wherein the second layer is adjacent to the first side of the first layer; and a third layer comprising a third biodegradable polymer, wherein the third layer encapsulates the first and second layers, and wherein at least one face of the device comprises an exposed second layer not coated by the third biodegradable polymer. In one aspect, the first and third biodegradable polymers are poly-ε-caprolactone, while the second biodegradable polymer is a mixture of cellulose acetate phthalate and a poloxamer. Also disclosed are methods for fabricating the devices.
In one aspect, this disclosure relates to nanoparticle compositions comprising a core a plurality of nanoparticles, each nanoparticle of the plurality comprising a core, wherein the core comprises a biocompatible copolymer, and each nanoparticle of the plurality further comprising an ionic liquid coating surrounding the core; methods of making the same; pharmaceutical compositions comprising same; and methods of treating neurological diseases and disorders using same. In one aspect, the biocompatible copolymer can be poly(lactic-co-glycolic acid). In another aspect, the nanoparticle compositions can include one or more pharmaceutical agents including, but not limited to, antiretroviral agents. In still another aspect, the ionic liquids can include choline and an anion derived from a substituted or unsubstituted C2-C20 linear or branched fatty acid. In any of these aspects, the nanoparticle compositions are capable of crossing the blood brain barrier.
In one aspect, the disclosure relates to ammonium carboxylic acid ionic liquids, methods of making the ionic liquids, pharmaceutical compositions comprising the same, and methods of treating both Gram-negative and Gram-positive bacterial infections using same. In one aspect, the ionic liquids are biocompatible with mammalian cells. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
In one aspect, the disclosure relates to charge-shifting polymers including a polymeric backbone, one or more tertiary amine-containing pendant groups, and at least one linker between the polymeric backbone and each of the one or more pendant groups, wherein the at least one linker comprises a thioester. Also disclosed are methods of making the same, compositions comprising the charge-shifting polymers and at least one therapeutic molecule, and methods of controlled intracellular release of therapeutic molecules including, but not limited to, small molecules, peptides and proteins, and nucleic acids using the same. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
C07C 215/08 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
C07C 321/06 - Thiols having mercapto groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
C08F 134/02 - Homopolymers of cyclic compounds having no unsaturated aliphatic radicals in a side chain and having one or more carbon-to-carbon double bonds in a heterocyclic ring in a ring containing oxygen
C08F 234/02 - Copolymers of cyclic compounds having no unsaturated aliphatic radicals in a side chain and having one or more carbon-to-carbon double bonds in a heterocyclic ring in a ring containing oxygen
12.
FLUOROALCOHOLS AS CO-SOLVENTS FOR CHEMICAL SYNTHESIS AND METHODS FOR PRODUCING THE SAME
in situd22 2 for hydroxydeuteromethylations and constitutes a new synthetic method for 2,2-difluoro-1,1-deuteroethanols. In one aspect, disclosed method is compatible with α,α-difluorobenzyl carbanions generated from the release of trifluoroacetate from electron-deficient aromatic and heteroaromatic rings and can be conducted under mild conditions with high yields. Also disclosed herein are 2,2-difluoroethanols generated by the disclosed method and methods of using the 2,2-difluoroethanols as solvents or co-solvents for organic synthesis, metal catalyzed reactions, asymmetric processes, carbohydrate chemistry, and medicinal chemistry.
C07C 31/38 - Halogenated alcohols containing only fluorine as halogen
C07C 29/74 - SeparationPurificationStabilisationUse of additives
C07C 33/02 - Acyclic alcohols with carbon-to-carbon double bonds
13.
Orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor with potential use towards visceral pain management and neurodegenerative disorders
The disclosure relates to compounds of Formula I, methods of making same, pharmaceutical compositions including same, and methods of treating pain and neurological disorders using same:
and wherein the bond indicated by * is a double bond or a single bond based on a valence of X.
The compounds selectively bind to CB2, can penetrate the blood brain barrier, and have a half-life of 20 hours or greater.
Mycobacterium tuberculosisMycobacterium tuberculosis using the same. In an aspect, the compounds and pharmaceutical compositions are not cytotoxic. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
B01J 2/10 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
17.
ALLOPREGNANOLONE ANALOGUES FOR HIV VIREMIA AND NEUROTOXICITY PROTECTION
In one aspect, the disclosure relates to pregnane neurosteroid analogues of 5a-pregnan-3a-ol-20-one (3a,5a-THP). Also disclosed herein are methods of making the same, pharmaceutical compositions comprising the same, and methods of treating HIV and/or neuroHIV using the same. The pharmaceutical compositions can alleviate at least one symptom associated with HIV and/or neuroHIV and can be used alone or in combination with other HIV therapies including combination antiretroviral therapy (cART).
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
In one aspect, the disclosure relates to pregnane neurosteroid analogues of 5α-pregnan-3α-ol-20-one (3α,5α-THP). Also disclosed herein are methods of making the same, pharmaceutical compositions comprising the same, and methods of treating HIV and/or neuroHIV using the same. The pharmaceutical compositions can alleviate at least one symptom associated with HIV and/or neuroHIV and can be used alone or in combination with other HIV therapies including combination antiretroviral therapy (cART).
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
19.
CANNABICHROMENE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME
Described herein are new derivatives of cannabichromene that are effective in treating or preventing pain in a subject. The new cannabichromene derivatives have improved bioavailability, which enhances their ability to treat or prevent pain. In one aspect, the cannabichromene derivatives have the structure I or the pharmaceutically acceptable salt thereof. Also described herein are methods for making and using the cannabichromene derivatives.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
20.
CANNABICHROMENE DERIVATIVES AND METHODS FOR MAKING AND USING THE SAME
Described herein are new derivatives of cannabichromene that are effective in treating or preventing pain in a subject. The new cannabichromene derivatives have improved bioavailability, which enhances their ability to treat or prevent pain. In one aspect, the cannabichromene derivatives have the structure I or the pharmaceutically acceptable salt thereof. Also described herein are methods for making and using the cannabichromene derivatives.
C07D 311/58 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulfur atoms in position 2 or 4
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
21.
METHODS FOR THE PULSED DELIVERY OF BIOACTIVE AGENTS
Described herein are methods for providing the pulsed delivery of a 5HT2A agonist to a subject upon administration of a device to the subject. The device is composed of biodegradable polymers such that when administered to the subject, the polymers on the surface of the device erode, releasing the bioactive agent. In one aspect, the device is composed of alternating layers of biodegradable polymers, where every other layer includes the bioactive agent. In a further aspect, one or more of the layers are composed of a mixture of cellulose acetate phthalate (CAP) and a poloxamer. The layers that do not include the bioactive agent functions as "blanks," which can be used to control the release rate of the bioactive agent. In a still further aspect, one or more sides of the device can be coated such that the bioactive agent is released from only one side of the device.
2A2A agonist to a subject upon administration of a device to the subject. The device is composed of biodegradable polymers such that when administered to the subject, the polymers on the surface of the device erode, releasing the bioactive agent. In one aspect, the device is composed of alternating layers of biodegradable polymers, where every other layer includes the bioactive agent. In a further aspect, one or more of the layers are composed of a mixture of cellulose acetate phthalate (CAP) and a poloxamer. The layers that do not include the bioactive agent functions as "blanks," which can be used to control the release rate of the bioactive agent. In a still further aspect, one or more sides of the device can be coated such that the bioactive agent is released from only one side of the device.
Provided herein are dyes, dye-sensitized solar cells, and sequential series multijunction dye-sensitized solar cell devices. The dyes include an electron deficient acceptor moiety, a medium electron density π-bridge moiety, and an electron rich donor moiety comprising a biaryl, a substituted biaryl, or an R1, R2, R3 substituted phenyl where each of R1, R2, and R3 independently comprises H, aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, OR4, N(R5)2, or a combination thereof, each R4 independently comprises H, alkyl, aryl, alkyl substituted aryl, alkoxy substituted aryl, or a combination thereof; and each R5 independently comprises aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, or a combination thereof. The solar cells include a glass substrate, a dye-sensitized active layer, and a redox shuttle. The devices include at least two dye-sensitized solar cells connected in series.
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
Described herein are new silicone-based compounds that have short wavelength infrared (SWIR) absorption and emission. The silicone-based compounds are readily accessible and obtainable on large scale with high purity through simple purification procedures. In one aspect, the silicone-based compounds have an absorption extending into the SWIR region and an emission maximum in the SWIR region which is promising for biological imaging applications.
Described herein are methods for reducing or preventing intraocular pressure in a subject. The methods involve administering to the subject a delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor. The combination of delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor is effective in reducing intraocular pressure when compared to independently the delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Described herein are methods for reducing or preventing intraocular pressure in a subject. The methods involve administering to the subject a delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor. The combination of delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor is effective in reducing intraocular pressure when compared to independently the delta-9-tetrahydrocannabinol amino acid ester or derivative thereof and the Rho kinase inhibitor.
Described herein are new silicone-based compounds that have short wavelength infrared (SWIR) absorption and emission. The silicone-based compounds are readily accessible and obtainable on large scale with high purity through simple purification procedures. In one aspect, the silicone-based compounds have an absorption extending into the SWIR region and an emission maximum in the SWIR region which is promising for biological imaging applications.
Disclosed are substantially pure L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives, and methods of use thereof. In particular, the presently disclosed subject matter relates to L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives thereof, and methods of treating cancer. The method comprises administering one or more substantially pure L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives to a subject in need thereof.
C07C 237/20 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
Compositions of a glycolysis inhibitor and a mitochondrial complex I inhibitor or glucose-6-phosphate dehydrogenase inhibitor are described. Methods of treating metabolic disorders by administration of a composition comprising glycolysis inhibitor and a mitochondrial complex I inhibitor or glucose-6-phosphate dehydrogenase inhibitor are also described. Also described are methods of inhibiting the proliferation of cancer cells by administration of a therapeutically effective amount of a composition comprising a glycolysis inhibitor and a mitochondrial complex I inhibitor or glucose-6-phosphate dehydrogenase inhibitor.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 31/566 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol having an oxo group in position 17, e.g. oestrone
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
30.
Design, synthesis, and photophysical properties of a novel NIR II dye for biological imaging and optoelectronic devices
In one aspect, the disclosure relates to fluorescent dyes that absorb and emit in the near infrared II (NIR II) range of the electromagnetic spectrum, methods of making same, compositions comprising same and methods of using the compositions to perform imaging on biological samples, and optoelectronic devices using the dyes. The dyes are small organic molecules that are inexpensive and facile to produce, can be water-soluble, have tunable properties, and are biocompatible and/or possess low toxicity.
A pharmaceutical composition is provided that comprises an effective amount of dillapiole or a derivative thereof, and a pharmaceutically-acceptable vehicle, carrier, or excipient. Methods of treating a bacterial infection are also described and include administering an effective amount of dillapiole or a derivative thereof to a subject in need of such treatment. Methods of reducing bacterial virulence are further described and include contacting a bacterium, such as a F. tularensis or A. baumannii bacterium, with an effective amount of dillapiole or a derivative thereof.
Described herein are novel topical compositions for treating peripheral neuropathic pain. The topical compositions include a cannabinoid and a fatty acid amide hydrolase inhibitor or a monoacylglycerol lipase inhibitor. The topical compositions may be used in the management of peripheral neuropathic pain.
Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
35.
Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same
Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07D 273/00 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
G01N 33/60 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances involving radioactive labelled substances
Biologically active cannabidiol analogs comprising a compound of the formula
2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
37.
L-Y-METHYLENEGLUTAMINE COMPOUNDS AND METHODS OF USE
Disclosed are substantially pure L-y-methyleneglutamine, L-y- methyleneglutamic acid, and/or amide derivatives, and methods of use thereof. In particular, the presently disclosed subject matter relates to L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives thereof, and methods of treating cancer. The method comprises administering one or more substantially pure L-y-methyleneglutamine, L-y-methyleneglutamic acid, and/or amide derivatives to a subject in need thereof.
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07C 237/28 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
Biologically active cannabidiol analogs comprising a compound of the formula
2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
39.
Twin-screw dry granulation for producing solid formulations
A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
B01J 2/10 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
Biologically active cannabidiol analogs comprising a compound of the formula
2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Biologically active cannabidiol analogs comprising a compound of the formula
2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Biologically active cannabidiol analogs comprising a compound of the formula
2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
A61K 31/235 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
43.
Dyes, dye-sensitized solar cells, and methods of making and using the same
5 independently comprises aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, or a combination thereof. The solar cells include a glass substrate, a dye-sensitized active layer, and a redox shuttle. The devices include at least two dye-sensitized solar cells connected in series.
C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
Provided herein are dyes, dye-sensitized solar cells, and sequential series multijunction dye-sensitized solar cell devices. The dyes include an electron deficient acceptor moiety, a medium electron density ?-bridge moiety, and an electron rich donor moiety comprising a biaryl, a substituted biaryl, or an R1, R2, R3 substituted phenyl where each of R1, R2, and R3 independently comprises H, aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, OR4, N(R5)2, or a combination thereof; each R4 independently comprises H, alkyl, aryl, alkyl substituted aryl, alkoxy substituted aryl, or a combination thereof; and each R5 independently comprises aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, or a combination thereof. The solar cells include a glass substrate, a dye-sensitized active layer, and a redox shuttle. The devices include at least two dye-sensitized solar cells connected in series.
H01L 51/00 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof
An apparatus for removing water vapor from a feed gas is provided that comprises a membrane housing, a membrane that divides a first pressure side and a second pressure side of the membrane housing, a feed gas inlet and outlet on the first pressure side, a sweep gas inlet and outlet on the second pressure side, a sweep gas flow regulator, and a pump. In some embodiments the feed gas can be at ambient pressure and a pressure drop across the membrane can be less than about 1 atm.
F24F 3/14 - Air-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by humidificationAir-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatmentApparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by dehumidification
Compositions of a glycolysis inhibitor and a mitochondrial complex I inhibitor or glucose-6-phosphate dehydrogenase inhibitor are described. Methods of treating metabolic disorders by administration of a composition comprising glycolysis inhibitor and a mitochondrial complex I inhibitor or glucose-6-phosphate dehydrogenase inhibitor are also described. Also described are methods of inhibiting the proliferation of cancer cells by administration of a therapeutically effective amount of a composition comprising a glycolysis inhibitor and a mitochondrial complex I inhibitor or glucose-6-phosphate dehydrogenase inhibitor.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 36/65 - Paeoniaceae (Peony family), e.g. Chinese peony
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
The present invention provides compositions and methods for treating or preventing a gram-positive bacterial infection. In one aspect, the composition comprises at least two cannabinoids.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
Anophies quadrimaculatus species of mosquitoes. The active fraction mainly comprises pure carotol. The essential oil and the pure compound have a potential to be developed and used as effective repellent against mosquitoes.
A01N 65/10 - Apiaceae or Umbelliferae [Carrot family], e.g. parsley, caraway, dill, lovage, fennel or snakebed
A01N 31/06 - Oxygen or sulfur directly attached to a cycloaliphatic ring system
A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
A01N 37/18 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N, e.g. carboxylic acid amides or imidesThio-analogues thereof
C07C 37/74 - SeparationPurificationStabilisationUse of additives by physical treatment by distillation
C07C 37/82 - SeparationPurificationStabilisationUse of additives by physical treatment by solid-liquid treatmentSeparationPurificationStabilisationUse of additives by physical treatment by chemisorption
C07C 37/00 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
C07C 37/86 - SeparationPurificationStabilisationUse of additives by treatment giving rise to a chemical modification
C07C 39/23 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
Compositions of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000 are described. Methods of administering nanolipid carrier molecules are also described. Also described is a method for treating fungal ocular infections by topical ocular administration of nanolipid carrier molecules comprising PEG molecules and solid and liquid lipids wherein the PEG has a molecular weight of between about 1000 and 5000.
Provided herein are dyes, dye-sensitized solar cells, and sequential series multijunction dye-sensitized solar cell devices. The dyes include an electron deficient acceptor moiety, a medium electron density ?-bridge moiety, and an electron rich donor moiety comprising a biaryl, a substituted biaryl, or an R1, R2, R3 substituted phenyl where each of R1, R2, and R3 independently comprises H, aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, OR4, N(R5)2, or a combination thereof; each R4 independently comprises H, alkyl, aryl, alkyl substituted aryl, alkoxy substituted aryl, or a combination thereof; and each R5 independently comprises aryl, multiaryl, alkyl substituted aryl, alkoxy substituted aryl, alkyl substituted multiaryl, alkoxy substituted multiaryl, or a combination thereof. The solar cells include a glass substrate, a dye-sensitized active layer, and a redox shuttle. The devices include at least two dye-sensitized solar cells connected in series.
Biologically active cannabidiol analogs comprising a compound of the formula
2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
C07C 233/56 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 229/24 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
55.
Symmetrical CCC-NHC pincer metal complexes and symmetrical bimetallic complexes: bio-activity, and applications to organic transformations and energy-related catalytic methods
Provided herein are a symmetrical pincer metal and bimetallic complexes. The symmetrical pincer metal complex includes a structure according to Formula I:
2TMS. The symmetrical bimetallic complex includes a structure according to Formula II:
2TMS. Also provided herein is a method of catalyzing a reaction including administering one or more of the compounds disclosed herein.
Δ9-Tetrahydrocannabinol (Δ9-THC or THC) and cannabidiol (CBD) are major constituents of the Cannabis plant that have pharmacological properties with potential therapeutic value. This invention is directed to processes for large scale isolation of these two and other cannabinoids from the Cannabis sativa plant. This is accomplished through the discovery that protected amino acid esters of the cannabinoids are easier to separate using normal phase silica column chromatography. Mild base hydrolysis of the esters regenerates the free cannabinoids in a purified form. The invention is also applicable to the isolation of other cannabinoids from Cannabis extracts.
?9-Tetrahydrocannabinol (?9-THC or THC) and cannabidiol (CBD) are major constituents of the Cannabis plant that have pharmacological properties with potential therapeutic value. This invention is directed to processes for large scale isolation of these two and other cannabinoids from the Cannabis sativa plant. This is accomplished through the discovery that protected amino acid esters of the cannabinoids are easier to separate using normal phase silica column chromatography. Mild base hydrolysis of the esters regenerates the free cannabinoids in a purified form. The invention is also applicable to the isolation of other cannabinoids from Cannabis extracts.
Methods are provided for treating an infectious disease of a subject with a composition which comprises an active ingredient that can be produced by bacteria of Paenibacillus or Bacillus. The disclosure also provides a composition or a pharmaceutical composition which comprises, or alternatively consists essentially of, or yet further consists of an active ingredient which can be produced by bacteria of Paenibacillus or Bacillus.
Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.
C07D 471/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational and entertainment services, namely, providing university level graduate and undergraduate courses of instruction, organizing and conducting college sporting events, athletic competitions and sports training programs
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational and entertainment services, namely, providing university level graduate and undergraduate courses of instruction, organizing and conducting college sporting events, athletic competitions and sports training programs
Sports and athletic clothing relating to a university and collegiate sports, namely, t-shirts, jerseys, sweat shirts, pants, hats, polo shirts, shorts, visors as headwear, socks, ties, sweaters and dresses, skirts, blouses, shirts, underwear, bras, sports bras, and jackets; t-shirts, jerseys, sweat shirts, pants, hats, polo shirts, shorts, visors as headwear, socks, ties being clothing, sweaters and dresses
41 - Education, entertainment, sporting and cultural services
Goods & Services
Educational and entertainment services, namely, providing university level graduate and undergraduate courses of instruction, organizing and conducting college sporting events, athletic competitions and sports training programs
Sports and athletic clothing relating to a university and collegiate sports, namely, t-shirts, jerseys, sweat shirts, pants, hats, polo shirts, shorts, visors as headwear, socks, ties, sweaters and dresses, skirts, blouses, shirts, underwear, bras, sports bras, and jackets; t-shirts, jerseys, sweat shirts, pants, hats, polo shirts, shorts, visors as headwear, socks, ties being clothing, sweaters and dresses
Sports and athletic clothing relating to a university and collegiate sports, namely, t-shirts, jerseys, sweat shirts, pants, hats, polo shirts, shorts, visors as headwear, socks, ties, sweaters and dresses, skirts, blouses, shirts, underwear, bras, sports bras, and jackets; t-shirts, jerseys, sweat shirts, pants, hats, polo shirts, shorts, visors as headwear, socks, ties being clothing, sweaters and dresses
69.
Laser multibeam differential interferometric sensor and methods for vibration imaging
A sensor for a vibration imaging system is provided. The sensor includes a transmitter configured to project an array of laser beams onto a surface of an object such that neighboring beams in the array of laser beams are frequency shifted relative to each other, an interferometer configured to mix radiations reflected from neighboring points on the surface of the object such that the radiations from neighboring points interfere with one another, a photodetector array configured to produce output signals representative of the interfering beams, a demodulator configured to demodulate the output signals, and a computing device configured to calculate a deformation profile for the object based on the demodulated output signals.
Natural products were screened for their insect repellent activity, and carrot seed essential oil gave very high activity in biting repellent/deterrent bioassays. Analysis of the oil revealed the presence of 47 compounds, mainly mono- and sesqui-terpenes. The sesquiterpene, carotol, constituted more than 75% w/w of the oil. In the initial screening, the essential oil gave high biting deterrent activity and high repellent activity comparable to DEET against both Aedes aegypti and Anophies quadrimaculatus species of mosquitoes. The active fraction mainly comprises pure carotol. The essential oil and the pure compound have a potential to be developed and used as effective repellent against mosquitoes.
A01N 35/04 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aldehyde or keto groups, or thio-analogues thereof, directly attached to an aromatic ring system, e.g. acetophenoneDerivatives thereof, e.g. acetals
A01N 31/04 - Oxygen or sulfur attached to an aliphatic side chain of a carbocyclic ring system
G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
A01N 37/06 - Unsaturated carboxylic acids or thio-analogues thereofDerivatives thereof
71.
Compositions for prevention/prophylactic treatment of poison ivy dermatitis
The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 229/36 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07C 237/04 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07C 237/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
C07D 209/12 - Radicals substituted by oxygen atoms
A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 9/00 - Medicinal preparations characterised by special physical form
A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
B01J 2/10 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
74.
TWIN-SCREW DRY GRANULATION FOR PRODUCING SOLID FORMULATIONS
A dry granulation process using a twin-screw extruder for granulating a powder mixture which includes at least one active ingredient and at least one carrier. The process includes steps of kneading the powder mixture in the screw barrel of the twin-screw extruder at a barrel temperature below a melting point of the at least one active ingredient and a melting point or a glass transition temperature of the at least one carrier to provide a kneaded powder mixture, and extruding the kneaded powder mixture to form granules. Granules and tablets produced using the dry granulation process in the twin-screw extruder are also provided.
Biologically active cannabidiol analogs comprising a compound of the formula [ I ] wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
Biologically active cannabidiol analogs comprising a compound of the formula [ I ] wherein one of R1 or R2 or both is/are the residue of a moiety formed by the reaction of an amino group of the amino acid ester of R1 or R2 or both with a dicarboxylic acid or a dicarboxylic acid derivative and the other R1 or R2 (in the case of the mono) is the residue of a dicarboxylic acid or dicarboxylic acid derivative or Hydrogen (H), (i.e. underivatized), and salts thereof. These CBD analogs are be useful in pain management in oncology and other clinical settings in which neuropathy is presented. Furthermore, these CBD-analogs are useful in blocking the addictive properties of opiates.
A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
C07C 69/017 - Esters of hydroxy compounds having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 233/48 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
78.
Methods for detecting and categorizing skin sensitizers
Methods for detecting skin sensitization chemical compounds using Nuclear Magnetic Resonance (NMR) spectroscopy and/or a microplate spectrophotometric assay or other spectroscopic methods. The presently disclosed subject matter relates to a method of detecting skin sensitization potential of a test chemical compound using Nuclear Magnetic Resonance (NMR) spectroscopy, microplate spectrophotometry or other spectroscopic methods as stand-alone or in combination.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.
Compositions are disclosed herein that include macrocycle derivatives incorporating bridged macrocycles. Also disclosed are methods of producing and using the compositions.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07D 273/00 - Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
81.
LASER MULTIBEAM DIFFERENTIAL INTERFEROMETRIC SENSOR AND METHODS FOR VIBRATION IMAGING
A sensor for a vibration imaging system is provided. The sensor includes a transmitter configured to project an array of laser beams onto a surface of an object such that neighboring beams in the array of laser beams are frequency shifted relative to each other, an interferometer configured to mix radiations reflected from neighboring points on the surface of the object such that the radiations from neighboring points interfere with one another, a photodetector array configured to produce output signals representative of the interfering beams, a demodulator configured to demodulate the output signals, and a computing device configured to calculate a deformation profile for the object based on the demodulated output signals.
G01B 11/25 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures by projecting a pattern, e.g. moiré fringes, on the object
The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3 -n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.
The present invention, in one or more embodiments, comprises derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3 -n-heptadecyl catechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising urushiol esters of general formula (IA) [Formula should be entered here] tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a formulation containing at least one urushiol ester compound.
The United States of America, as represented by The Secretary of Agriculture (USA)
University of Mississippi (USA)
Inventor
Rimando, Agnes M.
El-Alfy, Abir
Rahim, Md Al
Abstract
We report for the first time that pterostilbene, a natural analog of resveratrol, shows anxiolytic-like action by downregulating phosphorylated levels of ERKs in the hippocampus of mice. Mice administered pterostilbene (1-10 mg/kg BW) by oral gavage were subjected to the Elevated-plus maze (EPM) test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by an increase in percent permanence time and number of entries in open arms, critical determinants correlated with anxiety. This anxiolytic activity of pterostilbene was comparable to that of diazepam at 1 and 2 mg/kg in the EPM. The percent traveled distance and the percent permanence time in the enclosed arms were decreased with the 1 and 2 mg/kg doses. The 5 and 10 mg/kg doses did not show any anxiolytic effect. Locomotor activity was unaffected in all doses. Western blot analysis corroborated the observed behaviors in the EPM, revealing a decrease in both ERK1 and ERK2 phosphorylation in hippocampal homogenates from mice treated with 1 and 2 mg/kg doses; the 5 and 10 mg/kg doses showed no significant effect on the phosphorylation of ERKs. Pterostilbene was detected in serum and brain tissue following a single oral administration, demonstrating that the compound can cross the blood-brain barrier to reach the brain regions, including hippocampus, and thereby exert its anxiolytic effect. Resveratrol, the parent molecule of pterostilbene, did not have any anxiolytic effect.
Methods for detecting skin sensitization chemical compounds using Nuclear Magnetic Resonance (NMR) spectroscopy and/or a microplate spectrophotometric assay or other spectroscopic methods. The presently disclosed subject matter relates to a method of detecting skin sensitization potential of a test chemical compound using Nuclear Magnetic Resonance (NMR) spectroscopy, microplate spectrophotometry or other spectroscopic methods as stand-alone or in combination.
G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
87.
SYSTEMS AND METHODS FOR PREPARING SOLID LIPID NANOPARTICLES
A continuous process for the manufacture of solid lipid nanoparticles includes preparing a pre-emulsion comprising a lipid and continuously passing the pre-emulsion through a high pressure homogenizer.
A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
88.
HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS AND RADIOLIGANDS AS PROBES IN NOCICEPTIVE PROCESSING AND THE PATHPHYSIOLOGICAL STUDY OF MEMORY DEFICITS AND COGNITIVE DISORDERS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
THE UNIVERSITY OF MISSISSIPPI (USA)
Inventor
Mccurdy, Christopher R.
Mesangeau, Christophe
Chin, Frederick T.
James, Michelle L.
Shen, Bin
Gambhir, Sanjiv
Biswal, Sandip
Behera, Deepak
Abstract
Described herein is a non-therapeutic method of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising S1R-PET imaging a tissue with an imaging agent to determine a non-invasive biomarker of nerve injury and inflammation wherein the imaging agent comprises at least one S1R selective radioligand selected from the general formula III':wherein Ri is a radical of an optionally substituted piperazine, tetrahydropyridine, azepane or an tetrahydroisoquinoline in which the optional substituents are on the aromatic moiety or isoindoline-1,3-dione; R2,4,5 are each independently any one or combinations of hydrogen, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate, optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; Z is 0; "n" is 1 to 5 carbons; the moiety bridging Ri and N is a substituted alkylene; and X is tritium or Ci-C4 radiohaloalkyl; and stereoisomers, or pharmaceutically acceptable salts thereof.
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
89.
HIGHLY SELECTIVE SIGMA RECEPTOR LIGANDS AND RADIOLIGANDS AS PROBES IN NOCICEPTIVE PROCESSING AND THE PATHPHYSIOLOGICAL STUDY OF MEMORY DEFICITS AND CONITIVE DISORDERS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Mccurdy, Christopher, R.
Mesangeau, Christophe
Chin, Frederick, T.
James, Michelle, L.
Shen, Bin
Gambhir, Sanjiv
Biswal, Sandip
Behera, Deepak
Abstract
A method for localizing and quantifying SIR role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an SIR selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased SIR density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SRI selective compound or radioligand of the general formula III', or IV' :
A61K 31/428 - Thiazoles condensed with carbocyclic rings
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/00 - Drugs for disorders of the nervous system
90.
Compositions for prevention/prophylactic treatment of poison ivy dermatitis
The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I)
tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
C07C 67/08 - Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
C07C 67/14 - Preparation of carboxylic acid esters from carboxylic acid halides
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 237/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
C07D 209/12 - Radicals substituted by oxygen atoms
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
91.
Systems and methods for detecting transient acoustic signals
A two-scale array for detecting wind noise signals and acoustic signals includes a plurality of subarrays each including a plurality of microphones. The subarrays are spaced apart from one another such that the subarrays are configured to detect acoustic signals, and the plurality of microphones in each subarray are located close enough to one another such that wind noise signals are substantially correlated between the microphones in each subarray.
H04R 1/40 - Arrangements for obtaining desired frequency or directional characteristics for obtaining desired directional characteristic only by combining a number of identical transducers
G01H 5/00 - Measuring propagation velocity of ultrasonic, sonic or infrasonic waves
G10L 25/00 - Speech or voice analysis techniques not restricted to a single one of groups
G10L 21/0216 - Noise filtering characterised by the method used for estimating noise
Suppository, hot melt and ophthalmic formulations containing amino esters of the formulae (I), (II) and (III), where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
An underwater reconnaissance system includes an underwater reconnaissance platform configured to monitor conditions at a seafloor, carry at least one instrument, and deploy at least one instrument at the seafloor. The underwater reconnaissance system further includes a control station configured to monitor and control operation of the underwater reconnaissance platform, and a cable communicatively coupling the control station to the underwater reconnaissance platform.
B63C 11/48 - Means for searching for underwater objects
94.
Highly selective sigma receptor ligands and radioligands as probes in nociceptive processing and the pathphysiological study of memory deficits and cognitive disorders
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
Inventor
Mccurdy, Christopher R.
Mesangeau, Christophe
Chin, Frederick T.
James, Michelle L.
Shen, Bin
Gambhir, Sanjiv
Biswal, Sandip
Behera, Deepak
Abstract
A method for localizing and quantifying S1R role in nociceptive processing; for providing a guide to providing an analgesic therapy; of using an S1R selective ligand as a biomarker for pathphysiological study of memory deficits and cognitive disorders; or of detecting increased S1R density at the site of nerve injury arising from neuropathic pain comprising using as a probe at least one SR1 selective compound or radioligand of the general formula III′, or IV′:
C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 277/68 - Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 265/36 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
C07D 209/08 - IndolesHydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
C07D 209/10 - IndolesHydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
C07D 279/16 - 1,4-ThiazinesHydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
C07D 277/74 - Sulfur atoms substituted by carbon atoms
95.
Seeding of a workspace to optimize codec operations
Various embodiments are directed toward compressing and/or decompressing data communicated between one or more network devices (e.g., codec operations). In particular, embodiments are directed towards improving codec performance by seeding the computation workspace that may be used by various codec processors. The seeding data may be determined based on at least one characteristic of a particular codec and the characteristics of data that may be processed by the codec processor. Also, the codec processor may be employed to generate data for the codec workspace based on the determined seeding data. Workspace data may be generated by processing the seeding data with the same codec processor that is used for normal codec operations. The workspace generated from the seeding data may be stored for future use, such as, when a matched data stream arrives.
H04B 1/66 - Details of transmission systems, not covered by a single one of groups Details of transmission systems not characterised by the medium used for transmission for reducing bandwidth of signalsDetails of transmission systems, not covered by a single one of groups Details of transmission systems not characterised by the medium used for transmission for improving efficiency of transmission
H04L 29/06 - Communication control; Communication processing characterised by a protocol
Embodiments compress and encrypt data in a single pass to reduce inefficiencies that occur from compression and encrypting data separately. Typically, compression and encryption are implemented in separate functional units. This has a few disadvantages: 1) encryption cannot make use of compression state to further secure the message, 2) processed data is read and written twice, 3) additional space, time, and resources are consumed, and 4) it is more prone to potential cipher-attacks since the encryption stage is independent from compression. Embodiments overcome these disadvantages by structuring these operations so that both compression and encryption is executed within the same processing loop. Thus: 1) encryption is stronger due to the dependence on the compression state, 2) I/O buffers are accessed only once reducing overhead, 3) system footprint is reduced, and 4) cipher analysis is more complex since the decryption process cannot be separated from the decompression process.
H04L 9/28 - Arrangements for secret or secure communicationsNetwork security protocols using particular encryption algorithm
H04L 9/06 - Arrangements for secret or secure communicationsNetwork security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
97.
SYSTEMS AND METHODS FOR DETECTING TRANSIENT ACOUSTIC SIGNALS
A two-scale array for detecting wind noise signals and acoustic signals includes a plurality of subarrays each including a plurality of microphones. The subarrays are spaced apart from one another such that the subarrays are configured to detect acoustic signals, and the plurality of microphones in each subarray are located close enough to one another such that wind noise signals are substantially correlated between the microphones in each subarray.
G01R 23/167 - Spectrum analysisFourier analysis using filters with digital filters
G01R 29/027 - Indicating that a pulse characteristic is either above or below a predetermined value or within or beyond a predetermined range of values
G01S 7/52 - Details of systems according to groups , , of systems according to group
98.
SYSTEMS AND METHODS FOR DETECTING TRANSIENT ACOUSTIC SIGNALS
A two-scale array for detecting wind noise signals and acoustic signals includes a plurality of subarrays each including a plurality of microphones. The subarrays are spaced apart from one another such that the subarrays are configured to detect acoustic signals, and the plurality of microphones in each subarray are located close enough to one another such that wind noise signals are substantially correlated between the microphones in each subarray.
G01R 23/167 - Spectrum analysisFourier analysis using filters with digital filters
G01R 29/027 - Indicating that a pulse characteristic is either above or below a predetermined value or within or beyond a predetermined range of values
G01S 7/52 - Details of systems according to groups , , of systems according to group
99.
Collapsible three dimensional vector demonstration and measurement device
The present invention, in one or more embodiments, comprises water-soluble derivatives of 3-n-pentadecylcatechol (poison ivy urushiol saturated congener) and/or 3-n-heptadecylcatechol (poison oak urushiol saturated congener) as compositions for the prevention and/or prophylactic treatment of contact dermatitis caused by poison ivy and poison oak. The present invention is also directed towards processes for making such compounds. Disclosed are compounds which are effective for tolerizing and desensitizing a subject against allergens contained in plants of the Anacardiaceae and Ginkgoaceae families comprising water soluble urushiol esters of general formula (I)
Tolerizing and desensitizing mammals, including humans, to allergens contained in plants of the Anacardiaceae and Ginkgoaceae families is attained by administering a composition containing at least one water soluble urushiol ester compound.
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
C07D 205/00 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
C07D 209/12 - Radicals substituted by oxygen atoms
A61K 31/222 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
C07C 237/12 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
